Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 6/20 | 0.73 |
| ▸ | CPB1 | P15086 | 1/20 | 0.64 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.64 |
| ▸ | MMP2 | P08253 | 3/20 | 0.63 |
| ▸ | MMP9 | P14780 | 3/20 | 0.63 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.62 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.62 |
| ▸ | MMP1 | P03956 | 1/20 | 0.58 |
| ▸ | MMP3 | P08254 | 1/20 | 0.58 |
| ▸ | MMP7 | P09237 | 1/20 | 0.58 |
| ▸ | MMP13 | P45452 | 1/20 | 0.58 |
| ▸ | TGM2 | P21980 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20677210 | 1.00 | FOLH1 (0.73) | FOLH1CPB1CPB2MMP2MMP9 | |
| SCHEMBL19520890 | 0.96 | FOLH1 (0.68) | FOLH1CPB1CPB2MMP2MMP9 | |
| SCHEMBL19520892 | 0.96 | FOLH1 (0.68) | FOLH1CPB1CPB2MMP2MMP9 | |
| SCHEMBL21310132 | 0.93 | FOLH1 (0.64) | FOLH1CPB1CPB2MMP2MMP9 | |
| SCHEMBL4561005 | 0.91 | FOLH1 (0.78) | FOLH1CPB1CPB2MMP2MMP9 | |
| SCHEMBL806151 | 0.91 | FOLH1 (0.78) | FOLH1CPB1CPB2MMP2MMP9 | |
| SCHEMBL464715 | 0.91 | FOLH1 (0.78) | FOLH1CPB1CPB2MMP2MMP9 | |
| SCHEMBL27429289 | 0.90 | SIRT2 (0.69) | FOLH1CPB1CPB2SIRT2SIRT1 | |
| SCHEMBL31265517 | 0.88 | FOLH1 (0.69) | FOLH1CPB1CPB2MMP2MMP9 | |
| SCHEMBL13227705 | 0.88 | FOLH1 (0.69) | FOLH1CPB1CPB2MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564631-B2 | Phytosphingosine derivatives as adjuvants in immune stimulation | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2026-03-03 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240043379-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-02-08 | — | — | US | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| US-11806404-B2 | Site specific homogeneous with KSP inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-11-07 | — | — | US | disclosed |
| US-11806404-B2 | Site specific homogeneous with KSP inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-11-07 | — | — | US | disclosed |
| US-11806404-B2 | Site specific homogeneous with KSP inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-11-07 | — | — | US | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-06-27 | — | — | US | disclosed |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-06-27 | — | — | US | disclosed |
| US-10973923-B2 | Site specific homogeneous with KSP inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-04-13 | — | — | US | disclosed |
| US-20190262463-A1 | SITE SPECIFIC HOMOGENEOUS WITH KSP INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-08-29 | — | — | US | disclosed |
| US-20190262463-A1 | SITE SPECIFIC HOMOGENEOUS WITH KSP INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-08-29 | — | — | US | disclosed |
| US-20190077752-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-03-14 | — | — | US | disclosed |
| US-20190077752-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-03-14 | — | — | US | disclosed |
| EP-3432934-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | Bayer Pharma Aktiengesellschaft (DE) | 2019-01-30 | — | — | EP | disclosed |
| WO-2017162663-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017162663-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | WO | disclosed |
| WO-1991010644-A1 | CYCLOALKYL-SUBSTITUTED GLUTARAMIDE DIURETIC AGENTS | PFIZER LIMITED (GB) | 1991-07-25 | — | — | WO | disclosed |
| EP-0343911-A2 | Cycloalkyl-substituted glutaramide diuretic agents | Pfizer Limited (GB) | 1989-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11806404-B2 | Site specific homogeneous with KSP inhibitors | KIF5B, KIF15, KIF2C | FOLH1 690/4885CPB1 3003/4885CPB2 3487/4885 |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BUB1B, KIF5B, TK1 | FOLH1 317/4885CPB1 559/4885CPB2 643/4885 |
| US-20190262463-A1 | SITE SPECIFIC HOMOGENEOUS WITH KSP INHIBITORS | KIF5B, KIF15, KIF2C | FOLH1 690/4885CPB1 3003/4885CPB2 3487/4885 |
| US-20240043379-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BUB1B, KIF5B, TK1 | FOLH1 317/4885CPB1 559/4885CPB2 643/4885 |
| US-10973923-B2 | Site specific homogeneous with KSP inhibitors | KIF5B, KIF15, KIF2C | FOLH1 690/4885CPB1 3003/4885CPB2 3487/4885 |
| US-20190077752-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BUB1B, KIF5B, TK1 | FOLH1 317/4885CPB1 559/4885CPB2 643/4885 |
| US-12564631-B2 | Phytosphingosine derivatives as adjuvants in immune stimulation | HRH3, IL4I1, HRH4 | FOLH1 961/4885CPB1 2609/4885CPB2 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.